Navigation Links
Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

20 mg/kg, single or multiple doses) alone or in combination with dacarbazine, interleukin-2, or gp100 peptide vaccine. The primary endpoint of this analysis was to examine the kinetics of response to ipilimumab in 356 patients with stage III or stage IV metastatic melanoma; secondary endpoints included duration of objective response (defined as complete or partial response) and stable disease. Analysis of the kinetics of response data demonstrated:

    - Complete or partial response achieved in 13% (46/356) of patients.  Of

      these 46 patients:

      - 61% (28/46) achieved an objective response at week 12 or later

      - 35% (16/46) achieved stable disease prior to objective response

        (complete or partial)

      - 22% (10/46) achieved a partial response, which developed into a

        complete response

    - Current median duration of stable disease (from five of the six studies)

      was more than 15.4 weeks (median duration of objective response has not

      yet been reached).  Twenty-five patients continue to respond with the

      longest response still ongoing at five years.

As previously reported for each individual study, the most common adverse events were immune-related (irAEs) including rash and diarrhea, which were medically manageable and reversible with treatment.

"In some cases, responses were achieved at 12 weeks or later in patients whose disease progressed after treatment with ipilimumab, suggesting that continued treatment through apparent disease progression may be beneficial," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "Further research is needed to fully understand how immunotherapies differ from currently approved chemotherapies."

About Ipilimumab

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is believed to play a critical role in regulating natural
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:8/29/2014)... Research and Markets has announced ... Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the aspects ... and business performance of domestic major enterprises, as well ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop focused ... Zealand Forensic Science Society,s 22 nd International ... Adelaide, Australia .  Forensic Scientists will be ... hyperspectral imaging can bring to examination procedures. ... of Product Development at ChemImage, will host a ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... August 30, 2014 “In 2013, a vehicle ... Jones Firm says in a recently released article on ... was injured in an auto accident every 12 minutes, and ... they continue. “Based on the 2013 statistics, between now and ... collision.” , The threat of an auto accident is real ...
(Date:8/30/2014)... MA (PRWEB) August 30, 2014 Barton ... nurse practitioner locum tenens company , announces a ... September 1, 2014. Barton Associates is headquartered in Peabody, ... CT; Keene, NH; and Jupiter, FL. , ... to the increasing demand for healthcare providers. The United ...
(Date:8/30/2014)... 2014: The first multidisciplinary recommendations on the management ... (ACS) are published today in EP Europace ... by the European Heart Rhythm Association (EHRA), the ... Association of Percutaneous Cardiovascular Interventions (EAPCI), all of ... chairperson of the task force, said: "Sudden cardiac ...
(Date:8/30/2014)... Saturday 30 August 2014: The therapeutic benefit ... emphasised in the 2014 ESC/EACTS revascularisation guidelines presented ... Professor Stephan Windecker (Switzerland) of the European Society ... of the European Association for Cardio-Thoracic Surgery (EACTS). ... European Heart Journal (1), on the ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 AGH Healthy ... the Doctors in Delaware at Atlantic General ... free health-related services. In addition to no-cost blood pressure ... offers first aid care at local sports tournaments. ... other medical staff provide free disease management and falls ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 2Health News:ESC/EACTS revascularization guidelines stress benefit of revascularization in stable CAD 3Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 2Health News:Doctors in Delaware from Atlantic General Hospital Offer No-Cost Services to Area Residents 3
... The pharmaceutical industry is a "market for lemons," a ... buyer about the product and can profit from selling products ... believe, according to an analysis that will be presented at ... "Sometimes drug companies hide or downplay information about serious side ...
... study shows the impact of alcohol intoxication on reasoning ... feel they have recovered enough to drive after drinking. ... president of research for Lifespan, is the first to ... rising and declining blood alcohol concentrations, at matched blood ...
... , TUESDAY, Aug. 17 (HealthDay News) -- Nearly 40 percent ... episodes of manic behavior, a new study suggests. Researchers ... that these patients have what,s called "subthreshold hypomania" -- meaning ... days, and is therefore below the threshold for bipolar disorder. ...
... Community Living Assistance Services and Supports (CLASS) Act a ... Care Act has the potential to transform long-term care ... insurance-based system, according to the latest issue of ... With funding from The SCAN Foundation , this ...
... for airway repair in the lung but that persist in ... poor prognosis in patients who develop cancer, even those with ... have found. These adult stem cells are found in ... areas, suggesting that these cells may mutate and become cancer ...
... an Aging America" will be the focus of the 24th ... Aging from 8 a.m. to 3:30 p.m. Wednesday, Sept. 8 ... The conference, sponsored by The University of Texas Health ... Aging, will include panel discussions, a keynote address by Robert ...
Cached Medicine News:Health News:Pharmaceuticals: A market for producing 'lemons' and serious harm 2Health News:Pharmaceuticals: A market for producing 'lemons' and serious harm 3Health News:Why drunk drivers may get behind the wheel 2Health News:Why drunk drivers may get behind the wheel 3Health News:Many Depressed People Have Mild, Brief Episodes of Mania 2Health News:CLASS Act analysis reveals America's long-term care future 2Health News:Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor 2
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, starter package accessory ... adapter, specimen mounts 1/2" head, ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... Plus Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
... with a square vice mounting device. ... for mounting specimens and placing in ... blocks are annodized black for easy ... They are shipped three to ...
Medicine Products: